HEPA - Hepion Pharmaceuticals, Inc.

0.318
-0.074   -23.145%

Share volume: 4,368,896
Last Updated: 05-12-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$0.39
-0.07
-0.19%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 8%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
256.10%
2 Year
-87.77%
Key data
Stock price
$0.32
P/E Ratio 
N/A
DAY RANGE
$0.31 - $0.41
EPS 
-$3.00
52 WEEK RANGE
$0.02 - $0.99
52 WEEK CHANGE
$268.48
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
11.620 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-18-2025
NEXT EARNINGS DATE
08-12-2025
BETA 
1.27
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Robert T. Foster
Region: US
Website: hepionpharma.com
Employees: 20
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Hepion Pharmaceuticals, Inc. focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.

Recent news